Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye

This study has been completed.
Sponsor:
Information provided by:
Bausch & Lomb Incorporated
ClinicalTrials.gov Identifier:
NCT00560638
First received: November 19, 2007
Last updated: July 14, 2011
Last verified: July 2011
  Purpose

This was a single-center, randomized, double-masked, placebo-controlled, parallel-group, 4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects were randomized to receive loteprednol etabonate ophthalmic suspension, 0.5% or placebo (vehicle of loteprednol etabonate ophthalmic suspension, 0.5%) and instructed to dose bilaterally either TID or QID according to randomization.


Condition Intervention Phase
Dry Eye
Drug: loteprednol etabonate ophthalmic suspension, 0.5%
Drug: vehicle of loteprednol etabonate
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Masked, Randomized, Placebo-Controlled Study of Loteprednol Etabonate Ophthalmic Suspension, 0.5% for the Treatment of Dry Eye Used Either TID or QID for a 2 Week Period

Resource links provided by NLM:


Further study details as provided by Bausch & Lomb Incorporated:

Primary Outcome Measures:
  • Ocular discomfort during CAE exposure [ Time Frame: during CAE exposure ] [ Designated as safety issue: No ]
  • Corneal and conjunctival staining and conjunctival redness [ Time Frame: After CAE exposure ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Corneal and conjunctival staining and conjunctival redness [ Time Frame: before CAE exposure ] [ Designated as safety issue: No ]
  • Blink rate, Tear film break-up time (TFBUT), and Ocular Protection Index (OPI) [ Time Frame: before after CAE exposure ] [ Designated as safety issue: No ]
  • Ocular discomfort [ Time Frame: collected in patient diaries ] [ Designated as safety issue: No ]

Enrollment: 119
Study Start Date: November 2005
Study Completion Date: February 2006
Primary Completion Date: February 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Loteprednol Etabonate TID
loteprednol etabonate ophthalmic suspension, 0.5%, TID
Drug: loteprednol etabonate ophthalmic suspension, 0.5%
TID
Other Name: Lotemax
Experimental: Loteprednol Etabonate QID
loteprednol etabonate ophthalmic suspension, 0.5%, QID
Drug: loteprednol etabonate ophthalmic suspension, 0.5%
QID
Other Name: Lotemax
Placebo Comparator: Vehicle
vehicle of loteprednol etabonate
Drug: vehicle of loteprednol etabonate
TID or BID according to the randomization

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • at least 18 years of age or older
  • able and willing to follow instructions, including participation in study assessments and able be present for the required study visits for the duration of the study
  • If female and of childbearing potential, were not pregnant, nursing, or planning a pregnancy. Women of childbearing potential were required to have a negative urine pregnancy test at the pre-screen visit and had to agree to use an acceptable method of mechanical or hormonal contraceptive for the duration of the study
  • a diagnosis of dry eye
  • a history of intermittent or regular artificial tear use within the past 3 months
  • best corrected visual acuity (BCVA) of +0.7 or better assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in one or both eyes
  • a fluorescein staining score of ≥ 1+ in at least one region in at least one eye at Visit 1 and before CAE exposure at Visits 2 and 3 OR a fluorescein staining score of ≥ 1+ in at least one region in at least one eye at Visit 1 and before CAE exposure at Visits 2 and 3 with a conjunctival redness score of ≥ 1.5+ at Visit 1 and before CAE exposure at Visits 2 and 3 in at least one eye
  • Demonstrated a response when exposed to the CAE at Visits 2 and 3

Exclusion Criteria:

  • clinically significant blepharitis or Meibomian Gland Dysfunction (MGD) or lid margin inflammation, particularly if systemic or topical medications were currently being used to treat any of these diagnoses
  • diagnosed with an on-going ocular infection (bacterial, viral, or fungal), or active ocular inflammation (e.g. follicular conjunctivitis), or preauricular lymphadenopathy, particularly if systemic or topical medications were currently being used to treat any of these diagnoses
  • Reported an ocular discomfort score of 4+ in both eyes at time 0 of CAE exposure at Visits 2 or 3
  • Wore contact lenses and refused to remove them for the duration of the study
  • previous laser in situ keratomileusis (LASIK) surgery
  • currently taking any topical ophthalmic prescription (including medications for glaucoma) or over-the-counter (OTC) solutions, artificial tears, gels or scrubs and could not discontinue these medications for the duration of the study
  • presently taking any medication known to cause ocular drying that had not been a stable dose for at least 30 days
  • currently taking oral antihistamines that could not be discontinued during the study
  • a systemic disease, uncontrolled medical condition that in the opinion of the investigator could interfere with study measurements or subject compliance
  • received another experimental drug or device within 30 days prior to screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00560638

Locations
United States, Massachusetts
Ophthalmic Research Associates
Andover, Massachusetts, United States, 01810
Sponsors and Collaborators
Bausch & Lomb Incorporated
Investigators
Principal Investigator: Gail Torkildsen, MD Ophthalmic Research Associates, Inc.
  More Information

No publications provided

Responsible Party: Tuyen Ong, MD, Bausch & Lomb Incorporated
ClinicalTrials.gov Identifier: NCT00560638     History of Changes
Other Study ID Numbers: 439
Study First Received: November 19, 2007
Last Updated: July 14, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Eye Diseases
Keratitis
Corneal Diseases
Lacrimal Apparatus Diseases
Loteprednol etabonate
Anti-Allergic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 21, 2014